SCHERING's IMDUR HAD 26% OF GROWING ISOSORBIDE MONONITRATE MARKET

SCHERING's IMDUR HAD 26% OF GROWING ISOSORBIDE MONONITRATE MARKET in the six months ended Sept. 30, according to data from IMS America's NPA Plus data service. On a more than four-fold jump in scripts in its second six-month period on the U.S. market, Imdur generated 316,000 scripts between April and September of this year. In its first six-month period on the market, the product generated 73,000 scripts. In retail dollars, Imdur generated over $8 mil. in sales in the March-September period.